Alongside, Fms-related tyrosine kinase 3 (FLT3) mutations have also been evident in the disease encompassing almost 15–25% of all AML, with higher prevalence in younger patients (≤ 60 years). Here, FLT3 is linked to acute myeloid leukemia.